CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELirium

NCT07804498 · tracked via the Priya Life Science Italy tracker

Sponsor

University of Milano Bicocca

Phase

Phase 2

Started

2026-06-03

Last updated

2026-09-09

Condition(s) studied

Cognitive DeclineDelirium

Investigational drug(s) / intervention(s)

Citicoline →

Citicoline: Citicoline acts as a neuroprotective agent by supporting membrane integrity, modulating neurotransmission, and reducing oxidative stress and neuronal damage, with potential benefits on cognitive and functional recovery. However, no previous trials has investigated the effect of citicoline in preventing cognitive decline after delirium. Participants in the experimental arm of this study will receive citicoline (TRAUSAN) 1000 mg/day as an oral solution in single-dose 10 mL sachets (100 mg/mL), starting the day after hospital discharge, for a total duration of 6 months. 1 mL of citicoline solution contains 100 mg of citicoline (as sodium salt). Excipient(s) with known effects: 1 mL of Citicoline oral solution contains 200 mg of liquid sorbitol, 10 mg of glycerin, 1.8 mg of methyl parahydroxybenzoate, 0.42 mg of propyl parahydroxybenzoate, 1.4 mg of potassium sorbate, 0.012 mg of Ponceau 4R red, and other excipients.

Study summary

The aim of this study is to assess whether citicoline (TRAUSAN), a neuroprotective agent involved in membrane phospholipid synthesis and neurotransmission, can prevent or attenuate cognitive decline in older adults who develop perioperative delirium during hospitalization for proximal hip fracture. Delirium is a frequent and severe complication in this population and is associated with cognitive and functional deterioration, institutionalization, and mortality.

Participants will be randomly assigned (1:1) to receive citicoline 1000 mg/day for 6 months after discharge, or usual care. Cognitive and functional status will be evaluated at discharge and subsequently at 3 and 6 months follow-up visits.

Eligibility

Sex

ALL

Min age

65 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Individuals aged ≥65 who were admitted for a proximal hip fracture to the Orthogeriatric Unit and underwent hip fracture surgery (IRCCS San Gerardo dei Tintori Foundation, Monza) 2. Clinical diagnosis of delirium (arising from any cause), ascertained pre- or post-operatively using the 4AT score (cut-off ≥ 4/12) 3. Diagnosis of chronic vascular encephalopathy (corroborated by clinical documentation or previous cerebral imaging), i.e. evidence of neurological and cognitive disorder resulting from cerebrovascular accidents 4. Prognosis quoad vitam ≥ 3 months 5. Availability of a formal or informal caregiver who may help the participant to take the prescribed dose and follow the visit schedule 6. Informed consent, freely granted from the participant or from his/her legal guardian (or from an impartial witness in cases where the patient is unable to sign but clearly expresses the will to participate), and acquired before the randomization. Exclusion Criteria: 1. Diagnosis of severe dementia (defined by medical clinical records or by the presence of an AD8 score ≥6 and a Global Deterioration Scale score ≥6) 2. Current therapy with citicoline 3. Any contraindications to citicoline (TRAUSAN), including allergy to acetylsalicylic acid or excipients contained in the drug, previous adverse reactions to citicoline, hypertonia of the parasympathetic nervous system, low-sodium diet 4. Clinical conditions or situations other than the condition being studied, which in the opinion of the researchers could interfere with the study or not allow optimal participation 5. Persistent in-hospital delirium (≥ 6 days or still present 24 hours prior to discharge).

Primary outcome measure(s)

Assess potential differences in cognitive profiles 6 months post-randomization among older adults hospitalized for proximal hip fractures with perioperative delirium, comparing the intervention arm (citicoline,TRAUSAN) to the control arm — 6 months
Montreal Cognitive Assessment (MoCA) performed at discharge and at 6 months post-randomization

Trial sites (1)

Facility	City	Region	Status
IRCCS San Gerardo dei Tintori Foundation	Monza	Monza E Brianza	Recruiting

More University of Milano Bicocca trials in Italy

Prospective Observational Study Based on a Cohort of Geriatric Patients With Hip Fracture Treated in the Centers Belonging to the GIOG Group Recruiting

Vancomycin in Primary Sclerosing Cholangitis in Italy Recruiting

Bicocca Epidemiological Assessment of Cardiovascular Risk Factors Enrolling by invitation

ABlative Radiotherapy (for) Unfavorable Prostate Tumors Recruiting

Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence Recruiting

Other trials for the same condition

A New 360° Dual-task Based Protocol for the Pre-clinical In-hospital and At-home Rehabilitation of Elderly: DUAL-Rehab Recruiting

Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns Starting soon

MASCoD - Multidimensional Assessment of Subjective Cognitive Decline Recruiting

TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07804498 on ClinicalTrials.gov ↗ ← All trials in Italy